
CATalyst Council Releases First 2025 Market Insights Report: Feline Veterinary Care Emerges as Industry Growth Driver
ANNAPOLIS, Md.--(BUSINESS WIRE)--The CATalyst Council, the veterinary industry's leading authority on the feline market, today announced the release of the first volume of the 2025 CATalyst Feline Market Insights Report, a first-of-its-kind data-driven resource offering a comprehensive view into the shifting dynamics of feline healthcare, market behavior, and veterinary trends across the United States.
At a time when the broader market headwinds are challenging veterinary medicine, the feline segment is bucking the trend with remarkable, sustained growth. According to proprietary practice data from multiple leading industry sources, feline veterinary visits and practice revenues in the U.S. have been steadily growing since early 2023, in stark contrast to the continuing and well-publicized annual decline in overall companion animal veterinary clinical visits over those same two years.
'We're seeing strong evidence that feline veterinary care is resilient in the face of inflation and other pressures on pet-owning households,' said Kristin Wuhrman, CATalyst Council Vice Chair. 'Driven in part by growing cat ownership, cats present a clear opportunity to prioritize investment in a more modern, data-informed feline care ecosystem.'
Key findings include:
Feline clinical visits grew year-over-year in 2023 and 2024, while overall visits to veterinary practices in the U.S. (dominated by canine visits) declined, a departure from historical norms;
Cats represent a growing percentage of the pet population in U.S. households;
Growth in the household-owned feline population has continued at an elevated level since the onset of the pandemic, suggesting cat companionship is highly valued in the current environment;
The return-to-office movement and denser urban living of today's world favor cat ownership;
The report's novel, feline-specific analysis reveals new opportunities to address unmet needs in feline care, particularly around caregiver engagement, preventive care, and practice-level service models; and
Leading pet industry companies are prioritizing investment in M&A, product pipelines, and retail strategies to reflect these trends.
Supported by aggregated data from U.S. veterinary practices and pet owners, and across multiple sources, CATalyst Council's Market Insights initiative aims to equip the profession with a deep understanding of the feline veterinary market's trajectory. The data-driven analysis uncovered in this first quarterly volume is essential for industry executives, investors, veterinary teams, and innovators seeking to identify whitespace, prioritize strategic investments, and drive better outcomes for cats and their caregivers alike.
'Cats are quite different than dogs. Their psychological and medical care needs are distinct, and their market trajectories are increasingly divergent,' said Anne Ward, DVM, CATalyst Council Chair. 'This report gives the industry the market data needed to act decisively and strategically drive growth, supporting a healthier future for millions of cats and the caregivers who love them.'
The 2025 CATalyst Feline Market Insights Reports, expected to be released quarterly, are available exclusively to CATalyst Council sponsors. The Council will release high-level conclusions from the reports throughout the year through press releases and LinkedIn, designed to engage veterinary professionals, industry stakeholders, and decision-makers with digestible, evidence-based content.
To receive updates or inquire about the benefits of sponsorship, please visit catalystcouncil.org.
About CATalyst Council
CATalyst Council is a national organization dedicated to accelerating innovation in feline care and enhancing quality of life for cats and their people. CATalyst Council's vision is to ensure all companion cats receive lifelong care by using evidence-based resources, embracing community-wide relationships for optimal health outcomes, and celebrating the human-feline bond.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Simplify Healthcare's Benefits1™.Medicare Drives Over 30% of Nationwide PBP Submissions to CMS, Marking Over 7 Years as a Trusted Industry Leader
AURORA, Ill., June 06, 2025--(BUSINESS WIRE)--Simplify Healthcare, a recognized leader in enterprise software solutions for Payers, proudly announces that its flagship platform, Benefits1™.Medicare, played a key role once again in streamlining over 30% of Medicare Advantage (MA) Plan Benefit Package (PBP) submissions to the Centers for Medicare & Medicaid Services (CMS) this year. This milestone highlights the platform's transformative impact on benefit plan management and its integral role in supporting Payers across the nation. Benefits1™.Medicare continues to be the industry leader, enabling large-scale CMS bid submissions successfully for over 7 years, while also importing data seamlessly from the CMS-PBP software. Designed to handle the complexities of bid submission and accessible immediately (benefit updates can be started at any time independent of HPMS releases), the platform continues to set the standard for speed, accuracy, and compliance in PBP submissions with its seamless integration, robust reporting, global data updates, secure user roles, workflow automation and audit tracking capabilities. "Our customers relied on Benefits1™.Medicare to streamline over 30% of nationwide PBP submissions—proof of the trust we've earned and the efficiency our platform delivers year after year." — Ramesh Padri, VP of Product Delivery at Simplify Healthcare. "Managing the full Medicare Advantage lifecycle—from bids to digital delivery—makes Benefits1™.Medicare truly stand out in helping Payers drive value and improve member experiences." — Tasneem Chital, VP of Government Markets at Simplify Healthcare. Industry Leadership Through Customer Focus As healthcare organizations face increasing operational and regulatory challenges, Benefits1™.Medicare offers an effective solution that simplifies workflows while driving greater organizational efficiency. "This milestone reflects our long-standing commitment of partnering with health plans to successfully manage bid submissions. We bring the full stack partnership experience — people, thought leaders, product, and technology— towards delivering a superior bid submission experience for our customers." — Nirnay Patel, EVP & GM of Benefits1™ at Simplify Healthcare. About Simplify Healthcare Simplify Healthcare powers connected benefits and provider journeys for Payers through a scalable, enterprise-grade, secure, compliant, and configurable cloud-based software platform — Simplify Health Cloud™. We offer highly scalable, technology-centered document and translation management services to Payers through Simplify Docs™. We also empower industries with AI-native SaaS solutions designed to build and deploy digital solutions faster, better, and with embedded AI through SimplifyX™. View source version on Contacts Simplify HealthcarePhone: (844) 720-6678Email: info@


Business Wire
3 hours ago
- Business Wire
Simplify Healthcare's Benefits1™.Medicare Drives Over 30% of Nationwide PBP Submissions to CMS, Marking Over 7 Years as a Trusted Industry Leader
AURORA, Ill.--(BUSINESS WIRE)-- Simplify Healthcare, a recognized leader in enterprise software solutions for Payers, proudly announces that its flagship platform, Benefits1™.Medicare, played a key role once again in streamlining over 30% of Medicare Advantage (MA) Plan Benefit Package (PBP) submissions to the Centers for Medicare & Medicaid Services (CMS) this year. This milestone highlights the platform's transformative impact on benefit plan management and its integral role in supporting Payers across the nation. Benefits1™.Medicare continues to be the industry leader, enabling large-scale CMS bid submissions successfully for over 7 years, while also importing data seamlessly from the CMS-PBP software. Designed to handle the complexities of bid submission and accessible immediately (benefit updates can be started at any time independent of HPMS releases), the platform continues to set the standard for speed, accuracy, and compliance in PBP submissions with its seamless integration, robust reporting, global data updates, secure user roles, workflow automation and audit tracking capabilities. 'Our customers relied on Benefits1™.Medicare to streamline over 30% of nationwide PBP submissions—proof of the trust we've earned and the efficiency our platform delivers year after year.' — Ramesh Padri, VP of Product Delivery at Simplify Healthcare. 'Managing the full Medicare Advantage lifecycle—from bids to digital delivery—makes Benefits1™.Medicare truly stand out in helping Payers drive value and improve member experiences.' — Tasneem Chital, VP of Government Markets at Simplify Healthcare. Industry Leadership Through Customer Focus As healthcare organizations face increasing operational and regulatory challenges, Benefits1™.Medicare offers an effective solution that simplifies workflows while driving greater organizational efficiency. 'This milestone reflects our long-standing commitment of partnering with health plans to successfully manage bid submissions. We bring the full stack partnership experience — people, thought leaders, product, and technology — towards delivering a superior bid submission experience for our customers.' — Nirnay Patel, EVP & GM of Benefits1™ at Simplify Healthcare. About Simplify Healthcare Simplify Healthcare powers connected benefits and provider journeys for Payers through a scalable, enterprise-grade, secure, compliant, and configurable cloud-based software platform — Simplify Health Cloud™. We offer highly scalable, technology-centered document and translation management services to Payers through Simplify Docs™. We also empower industries with AI-native SaaS solutions designed to build and deploy digital solutions faster, better, and with embedded AI through SimplifyX™.